|
|
|
| Efficacy of Double Filtration Plasmapheresis Combined with Immunosuppressant in the Treatment of Severe Lupus Nephritis and Its Influence on Levels of Peripheral Blood Alb BUN and WBC |
| WAN Weibo, LU Rong, XIONG Rong, et al |
| Wuhan First Hospital, Hubei Wuhan 430000, China |
|
|
|
|
Abstract Objective: To observe the efficacy of double filtration plasmapheresis (DFPP) combined with immunosuppressant in the treatment of severe lupus nephritis (LN) and its influence on the levels of peripheral blood urinary Albumin (Alb), blood urea nitrogen (BUN) and white blood cell (WBC). Methods: Patients with severe lupus nephritis who were treated in the hospital between January 2019 and December 2020 were retrospectively analyzed, and they were divided into observation group (n=67) and routine group (n=75) according to the treatment regimens. The routine group was treated with immunosuppressant and hormone, and the observation group was administered double filtration plasmapheresis on this basis. The clinical efficacy, liver-kidney function indicators, immune indicators and occurrence of adverse reactions were compared between the two groups after 6 months of treatment. Results: After treatment, the total remission rate of observation group was significantly higher than that of routine group (93.33% vs 79.10%) (P<0.05). After 6 months of treatment, the levels of Alb and serum total bilirubin (TBIL) of the two groups of patients were significantly enhanced compared to before treatment (P<0.05) while the levels of BUN, serum creatinine (Scr) and urine protein were significantly decreased compared to before treatment (P<0.05), and the differences between the groups were statistically significant after treatment (P<0.05). There was no statistical significance in the difference of urine protein before and after treatment between the two groups (P>0.05), and there were statistical significance in the differences of Alb, BUN, Scr and TBIL (P<0.05). After 6 months of treatment, the positive rate of anti-DsDNA antibody and levels of WBC and vascular cell adhesion molecule-1 (VCAM-1) in the two groups were significantly lower than those before treatment (P<0.05) while the level of complement C3 was significantly higher than that before treatment (P<0.05), and there were statistically significant differences between the two groups after treatment (P<0.05). There was no statistical significance in the difference of positive rate of DsDNA antibody before and after treatment between the two groups(P>0.05), but there were statistical significance in the differences of WBC level, urine VCAM-1 level and complement C3 level (P<0.05). During treatment, the incidence rate of adverse reactions was 18.67% in observation group and was 14.93% in routine group respectively (P>0.05). Conclusion: Immunosuppressant combined with DFPP has a better effect in the treatment of severe lupus nephritis. It can effectively improve the liver-kidney function, regulate the immune level and accelerate the recovery of disease, and it has safety of medication and is recommended for clinical application.
|
|
|
|
|
|
[1] 张铭明,张锐,杨小珂,等.PDGF-B和PDGFR-β蛋白在狼疮性肾炎中的表达及临床意义[J].国际检验医学杂志,2021,42(5):549~553.
[2] 李智.分析吗替麦考酚酯与激素联合应用治疗狼疮性肾炎的临床疗效[J].黑龙江医药,2021,34(3):603~605.
[3] 朱兴华,罗伟雄,陈璐,等.血浆吸附改善重症狼疮性肾炎并肾损伤患者免疫功能和预后的前瞻性对照研究[J].广东医学,2017,38(5):713~716.
[4] 劳万生.双重血浆置换治疗狼疮性肾炎伴血栓性微血管病的临床疗效[J].医学临床研究,2016,33(8):1613~1614.
[5] M C,Hochberg.Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus.[J].Arthritis and rheumatism,1997,40(9):1725.
[6] 时业惠.他克莫司联合泼尼松治疗狼疮性肾炎的临床效果[J].吉林医学,2021,42(3):623~625.
[7] 章海涛,周敏林,代敏.双重血浆置换联合免疫抑制剂治疗重症狼疮性肾炎的疗效[J].肾脏病与透析肾移植杂志,2019,28(1):13~18.
[8] 高璠,汪鑫,杨冉,等.HMGB1/TLR4介导狼疮性肾炎肾小球细胞增殖和细胞外基质沉积[J].中国药理学通报,2021,37(1):125~131.
[9] 韩梅,严小倩,鲁盈,等.血趋化因子CX3CL1和尿血管细胞黏附分子-1对狼疮肾炎疾病活动度的评价[J].浙江医学,2019,41(16):1718~1721.
[10] 秦军建,邢艳芳,江艳球,等.小剂量霉酚酸酯与环磷酰胺诱导治疗严重狼疮肾炎疗效比较[J].中国中西医结合肾病杂志,2019,20(11):975~978.
[11] 刘娜,马忠正,严慧芳,等.双重血浆置换联合激素与免疫抑制剂治疗儿童重症紫癜性肾炎的临床效果[J].中国当代儿科杂志,2019,21(10):955~959. |
|
|
|
2022, Vol. 28 
